A61671h419 business ethics ( discussion forum 7 ) | BA 616 Business Ethics | Campbellsville University
It depends on the circumstances. Generally speaking, I would be open to voluntary disclosure of study information as long as it did not pose a risk to public health or safety. This is because transparency is key for building trust and credibility with customers, potential partners, and other stakeholders. Additionally, by voluntarily disclosing study information it can also help increase awareness of the drug and its benefits which could potentially lead to increased demand for it.